IMFINZI is used to treat a type of lung cancer called non-small cell lung cancer (NSCLC) in adults. It is used when your NSCLC: has responded or stabilised after initial treatment with chemotherapy and radiotherapy.

Imfinzi is a medicine used to treat lung cancer. It is for use in adults with: non-small cell lung cancer (NSCLC) that is locally advanced (meaning it has spread into tissues around the lungs, but not to other parts of the body) and cannot be removed by surgery and is not getting worse after radiation treatment and platinum-based chemotherapy ...

Imfinzi( durvalumab) An overview of Imfinzi and why it is authorised in the EU . What is Imfinzi and what is it used for? Imfinzi is a medicine used to treat lung cancer. It is for use in adults with: • non-small cell lung cancer (NSCLC) that is locally advanced (meaning it has spread into tissues

IMFINZI, in combination with tremelimumab-actl and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor...

IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy (see …

Durvalumab, [8] sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. [6] It was developed by Medimmune/AstraZeneca. [9] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 . [6]

the Committee deems that IMFINZI (durvalumab) 50 mg/mL concentrate for solution for infu-sion provides a minor clinical added value (CAV IV) compared to gemcitabine + cisplatin chemotherapy in the first-line treatment of adults with unresectable or metastatic biliary tract cancer (BTC). © – 3

Sep 24, 2018 · Imfinzi is approved for the treatment of patients with unresectable, Stage III (locally-advanced) NSCLC in the US, Canada, Switzerland, India, Japan and Brazil. Other global health authority reviews and submissions are ongoing.

Dec 9, 2024 · Imfinzi (durvalumab) is an immunotherapy used to treat types of lung cancer (NSCLC, SCLC), bile duct and gallbladder cancer, hepatocellular carcinoma, and endometrial cancer. Includes Imfinzi side effects, interactions, indications, and package insert.

IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy (see …